文献速递细菌感染、耐药与抗菌药物

荷兰2003-16年DTPa-HBV-IPV/Hib疫苗对侵袭性b型流感嗜血杆菌病的有效性:病例对照研究

Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.
PubMed 文献 · Lancet Infect Dis · 2018-05-08

该病例对照研究纳入2003年1月1日至2016年12月31日荷兰5岁以下b型流感嗜血杆菌(Hib)感染病例159例及匹配对照1590例,评估六价DTPa-HBV-IPV/Hib疫苗有效性。总体疫苗有效性为92.8%(95%CI 88.7-95.4),不同发病年份无差异(p=0.9670),五价及其他疫苗与六价疫苗有效性无差异(OR 0.72,95%CI 0.36-1.45;p=0.3591)。疫苗有效性在1-2岁最高(97.1-99.0%),3-4岁最低(60.7-82.3%;p=0.0008),随年龄增长而减弱。

要点

  • 总体疫苗有效性为92.8%(95%CI 88.7-95.4),不同发病年份间无差异(p=0.9670)。
  • 五价及其他疫苗与六价疫苗有效性无差异:91.8%(95%CI 86.1-95.1)vs 94.0%(95%CI 89.0-96.8),OR 0.72(95%CI 0.36-1.45;p=0.3591)。
  • 疫苗有效性在1-2岁最高(97.1-99.0%),3-4岁最低(60.7-82.3%;p=0.0008)。

核心结论

  • 结果支持现行疫苗接种规划,Hib疫苗有效性未随时间推移或六价DTPa-HBV-IPV/Hib疫苗的引入而下降。
  • 疫苗有效性高但随年龄增长而减弱,Hib疾病增加的其他解释仍需评估。

研究设计与样本

  • 在荷兰进行的病例对照研究,病例来自荷兰细菌性脑膜炎参考实验室监测记录,对照来自全国疫苗接种登记系统Praeventis,每例匹配10名对照(按出生日期匹配)。
  • 纳入2003年1月1日至2016年12月31日发病、年龄小于5岁的Hib感染病例,共纳入170例报告病例中的159例(94%)及1590名匹配对照。
  • 采用条件logistic回归估计疫苗有效性,以最后记录的疫苗剂量将儿童分类为接种六价DTPa-HBV-IPV/Hib疫苗、五价疫苗(不含乙型肝炎病毒成分)或其他疫苗。

主要发现

  • 159例病例中91例(57%)已接种疫苗,1590名对照中1408名(89%)已接种疫苗。
  • 总体疫苗有效性为92.8%(95%CI 88.7-95.4),发病年份间无差异(p=0.9670)。
  • 五价及其他疫苗的有效性为91.8%(95%CI 86.1-95.1),六价疫苗为94.0%(95%CI 89.0-96.8),两者无差异(OR 0.72,95%CI 0.36-1.45;p=0.3591)。
  • 疫苗有效性在发病时1-2岁儿童中最高(97.1-99.0%),在3-4岁儿童中最低(60.7-82.3%;p=0.0008)。
  • 病例和对照的中位年龄为1.5岁(IQR 0.8-2.9)。

局限性

  • 170例报告病例中11例无法与Praeventis疫苗接种记录交叉匹配。
  • 疫苗有效性随年龄增长而减弱,Hib疾病增加的其他解释仍需评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2016, an increase in invasive Haemophilus influenzae serotype b (Hib) disease was reported in the Netherlands in children younger than 5 years, which coincided with the introduction of the hexavalent diphtheria, tetanus, and acellular pertussis-hepatitis B virus-inactivated polio virus/Hib vaccine (DTPa-HBV-IPV/Hib) from 2011 onwards. We aimed to estimate the effectiveness of the hexavalent vaccine to assess whether this increase could be explained by decreasing effectiveness. METHODS: We did a case-control study in the Netherlands. We selected patients with a Hib infection (cases) by use of the surveillance records of the Netherlands Reference Laboratory for Bacterial Meningitis (Amsterdam). Cases with a Hib infection that began from Jan 1, 2003, to Dec 31, 2016, and who were younger than age 5 years were included. Ten controls from the national vaccination register (Praeventis) were selected for each case, matched by date of birth. Vaccination status was ascertained by use of Praeventis, which details the vaccination records of children living in the Netherlands. The last recorded vaccine dose was used to classify the child as having received the hexavalent DTPa-HBV-IPV/Hib vaccine or a pentavalent vaccine (which excludes the hepatitis B virus component) or another vaccine. We estimated the effectiveness of these vaccines by use of conditional logistic regression. FINDINGS: We included 159 (94%) of 170 cases reported and 1590 matched controls, who had a median age of 1·5 years (IQR 0·8-2·9). The remaining 11 cases could not be cross-matched with vaccination records from Praeventis. 91 (57%) of 159 cases had been vaccinated, compared with 1408 (89%) of 1590 controls. The overall vaccine effectiveness was 92·8% (95% CI 88·7-95·4), with no differences between the year of disease onset (p=0·9670). There were no differences conferred by type of vaccine given: vaccine effectiveness of the pentavalent and other vaccines was 91·8% (95% CI 86·1-95·1) versus 94·0% (89·0-96·8) for the hexavalent vaccine (OR 0·72, 95% CI 0·36-1·45; p=0·3591). Vaccine effectiveness was highest in children aged 1-2 years at disease onset (97·1-99·0%) and was lowest in children aged 3-4 years at disease onset (60·7-82·3%; p=0·0008). INTERPRETATION: Our results support the current vaccination programme, since Hib vaccine effectiveness has not decreased over time or by the introduction of the hexavalent DTPa-HBV-IPV/Hib vaccine. Vaccine effectiveness was high but waned with age. Alternative explanations for the increase in Hib disease therefore need to be assessed. FUNDING: Dutch Ministry of Health, Welfare and Sports.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Monge S, Hahné SJ, de Melker HE, et al. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study. Lancet Infect Dis. 2018. PMID: 29752131. doi:10.1016/S1473-3099(18)30166-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。